when were glp-1 agonists approved for weight loss Rx Trends: Real-World Data on GLP-1s GLP-1 medications are marketed to

SGLT-2 Inhibitors: The Gap Seems to Be Leveling Off

95 Lixisenatide is a short-acting GLP-1RA agent, 96,97 and once-daily lixisenatide can improve patient compliance to a certain extent and reduce the occurrence of hypoglycemia

In addition to achieving significant weight loss, research has shown that GLP-1 drugs can reduce the risk of major cardiovascular events such as heart attack or stroke in people with Type 2 diabetes

Approval of tirzepatide for apnea was given on the basis of a study that showed the drug reduced the condition by up to 62.8 percent

JCI Insight 6 , e153732 (2021)

During this time, it was found that 17% of the participants had a history of psychiatric conditions, with insomnia being the most frequently reported issue